Clinical regulatory affairs is a precision discipline. Every document, every deadline, and every FDA correspondence carries compliance and legal weight. Yet a significant portion of the daily workload in regulatory affairs — document routing, version tracking, distribution coordination, deadline management — is fundamentally administrative rather than scientific. It is work that requires organizational discipline and process adherence, not regulatory expertise.
When that administrative work falls to regulatory scientists and affairs managers, the cost is twofold: strategic and scientific work is displaced, and administrative tasks are performed by professionals at three to five times the cost of what an experienced VA would require.
IND Submissions: Document Coordination at Scale
An IND application under 21 CFR 312 is a living regulatory file. Initial IND submissions require assembly of the Investigator's Brochure (IB), clinical protocol, Phase I study design, investigator qualifications, and CMC (chemistry, manufacturing, and controls) information. Once the IND is in effect, annual reports, safety reports, protocol amendments, and CMC updates must be submitted on defined timelines.
According to the Regulatory Affairs Professionals Society (RAPS), the average IND-stage program generates more than 30 regulatory submissions per year across protocol amendments, safety reports, and annual updates. Each submission requires document collection from multiple functional teams, formatting and completeness review, eCTD compiling or cover letter preparation, and submission confirmation and receipt documentation.
A regulatory affairs VA coordinates this document pipeline: tracking submission deadlines on the regulatory calendar, sending collection requests to functional teams (clinical, safety, CMC), receiving and organizing incoming documents, conducting completeness checks against the submission checklist, and preparing submission packages for the regulatory scientist's final review and sign-off. The VA owns the logistics; the regulatory professional owns the content.
FDA Correspondence: Tracking Without Dropping the Ball
FDA correspondence — information requests, clinical holds, meeting responses, and amendment acknowledgment letters — requires a documented response and follow-up process. In programs with active INDs, FDA interactions can be frequent, and failure to respond within required timeframes (e.g., FDA information requests under 21 CFR 312.62 typically require a 30-day response) has direct regulatory consequences.
A clinical regulatory VA maintains a correspondence tracker that logs every incoming FDA communication, the response deadline, the responsible regulatory lead, and the response status. When responses are approaching their deadline without a completed draft, the VA escalates to the responsible team member. When responses are submitted, the VA archives the correspondence and FDA receipt confirmation in the regulatory file.
Protocol Amendment Distribution: A Site Communication Function
When a protocol amendment is approved by the FDA (or is exempt from FDA review under 21 CFR 312.30), it must be distributed to all active clinical sites, and sites must acknowledge receipt, obtain local IRB approval, and implement the amendment before proceeding under revised protocol requirements. Coordinating this distribution and tracking acknowledgment across dozens of sites is a time-consuming administrative task that regulatory coordinators frequently delay because of competing priorities.
A VA manages the amendment distribution workflow: sending amendment packages to all active sites, tracking receipt acknowledgments, logging local IRB approval dates per site, maintaining a distribution tracking matrix for sponsor and FDA reference, and following up with non-responding sites on a defined schedule.
Investigator Brochure Updates: Version Control as Compliance
The Investigator's Brochure is updated as new safety and efficacy data emerge throughout development. Each new edition must be distributed to investigators and sites, and prior versions must be archived with clear supersession documentation. Managing IB version control across a multi-site trial is an administrative function that directly supports GCP compliance — and one that VAs can own entirely.
Regulatory teams ready to offload document coordination and correspondence tracking can learn more at Stealth Agents.
Sources
- Regulatory Affairs Professionals Society (RAPS), Regulatory Operations Workforce Survey 2024
- FDA, 21 CFR Part 312 — Investigational New Drug Application
- PhRMA, Clinical Development Pipeline and Regulatory Activity Report 2024
- ICH M4E(R2) — Common Technical Document for the Registration of Pharmaceuticals